دورية أكاديمية

Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome. An international observational study

التفاصيل البيبلوغرافية
العنوان: Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome. An international observational study
المؤلفون: Verboon C., Harbo T., Cornblath D. R., Hughes R. A. C., Van Doorn P. A., Lunn M. P., Gorson K. C., Barroso F., Kuwabara S., Galassi G., Lehmann H. C., Kusunoki S., Reisin R. C., Binda D., Cavaletti G., Jacobs B. C. H. Andersen, MD, PhD (Aarhus University Hospital, Aarhus Denmark), S. Attarian, PhD (CHU Timone, Marseille France), U. A. Badrising, PhD (Leiden University Medical Centre, Leiden, The Netherlands), K. Bateman, PhD (Groote Schuur Hospital, Cape Town, South-Africa), L. Benedetti, PhD (Ospedale Sant’ Andrea La Spezia, La Spezia, Italy), B. van den Berg, MD (Franciscus Gasthuis, Rotterdam, P. Van den Bergh, PhD (University Clinic St. Luc, Leuven Belgium), T. E. Bertorini, MD (The University of Tennessee Health Science Center (UTHSC), Memphis USA), R. Bhavaraju-Sanka, MD (University Hospital/ University of Texas Health Science Center, San Antonio Texas, USA), M. Bianco (Milan University, Humanitas Clinicala and Research Institute Milan, C. Briani, MD (University of Padova, Padova Italy), J. Bürmann, MD (Universitätsklinikum des Saarlandes, Homburg Germany), C. Casasnovas, PhD (Bellvitge University Hospital - IDIBELL Neurometabolic Diseases Group. CIBERER, Barcelona Spain), C. C. Chao, PhD (National Taiwan University Hospital, Taipei Taiwan), G. Chavada, PhD (Glasgow University, Glasgow UK), K. G. Claeys, PhD (1. University Hospitals Leuven, Leuven Belgium, 2. KU Leuven, J. S. Cosgrove, MD (Leeds General Infirmary, Leeds UK), M. C. Dalakas, MD (1. Thomas Jefferson University, Philadelphia USA, 2. National and Kapodistrian University of Athens, Athens Greece), A. Davidson, MD (University of Glasgow, G. W. van Dijk, MD (Canisius Wilhelmina Hospital, Nijmegen, E. Dardiotis, MD (University of Thessaly, Hospital of Larissa, Larissa Greece), M. Derejko, MD (Odense University Hospital, Odense Denmark), M. M. Dimachkie, MD (University of Kansas Medical Center, Kansas City, C. Dornonville de la Cour, MD (National Hospital Copenhagen, Copenhagen Denmark), A. Echaniz-Laguna, MD (Bicêtre University Hospital, Paris France), F. Eftimov, PhD (Amsterdam University Medical Centre, Amsterdam, C. G. Faber, PhD (Maastricht University Medical Centre, Maastricht, R. Fazio, MD (Scientific Institute San Raffaele, Milan Italy), J. Fehmi (University of Oxford E. A. Fulgenzi, MD (Hospital Cesar Milstein Buenos Aires, Buenos Aires, Argentina), T. García-Sobrino, MD (Hospital Clínico de Santiago, Santiago de Compostela (A Coruña), Spain), C. J. Gijsbers, MD (Vlietland Hospital, Schiedam, V. Granit, MD (Montefiore Medical, Center, New York, S. Grisanti, MD (Ospedale Sant’ Andrea La Spezia, G. Gutiérrez-Gutiérrez, MD (Hospital Universitario Infanta Sofia, San Sebastian, J. V. Holbech, PhD (Odense University Hospital, J. K. L. Holt, PhD, FRCP (The Walton Centre, Liverpool UK), C. Homedes, MD (Bellvitge University Hospital - IDIBELL Neurometabolic Diseases Group. CIBERER, B. Islam, PhD (International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b) Dhaka, Bangladesh), Z. Islam, I. Jahan, PhD candidate (International Centre for Diarrhoeal Disease Research, I. Jericó Pascual, PhD (Complejo Hospitalario de Navarra, Pamplona Spain), S. Karafiath, MD (University of Utah School of Medicine, Salt Lake City, H. Kerkhoff, PhD (Albert Schweitzer Hospital, Dordrecht, K. Kimpinski, MD (University Hospital, LHSC London-Ontario, Canada), A. Kohler, MD (Instituto de Investigaciones Neurológicas Raúl Carrea, FLENI, N. Kolb, MD (University of Vermont, Burlington VT, K. Kuitwaard, PhD (1. Albert Schweitzer Hospital, 2. Erasmus MC, M. Kuwahara, PhD (Kindai University, Osaka Japan), S. S. Ladha, MD (Barrow Neurology Clinics, Phoenix Arizona, E. Lee Pan, MBChB (Groote Schuur Hospital, G. A. Marfia, MD (Neurological Clinic, Policlinico Tor Vergata, Rome Italy), A. Magot, MD (Reference Centre for NMD, Nantes University Hospital, France), C. Márquez Infante, MD (Hospital Universitario Virgen del Rocio, Seville Spain), L. Martín-Aguilar, MD (Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, E. Martinez Hernandez, MD (Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, G. Mataluni, PhD (Neurological Clinic, G. Meekins, MD (University of Minnesota, J. A. L. Miller, PhD (Royal Victoria Infirmary, Newcastle UK), M. S. Monges, MD (Hospital de Pediatría J. P. Garrahan, E. Nobile Orazio, PhD (Milan University, A. Pardal, MD (Hospital Britanico, J. Pardo Fernandez (Hospital Clínico de Santiago, Y. Péréon, PhD (Reference Centre for NMD, M. Pulley, MD (University of Florida, Jacksonville USA), L. Querol Gutierrez, PhD (Hospital de la Santa Creu i Sant Pau, S. W. Reddel, PhD (Concord Repatriation General Hospital, Sydney Australia), T. van der Ree, MD (Westfriesgasthuis, Hoorn, S. Rinaldi, MBChB, PhD (University of Oxford J. P. A. Samijn, MD (Maasstad Hospital, M. Samukawa, L. Santoro, PhD (University Federico II, Napels Italy), A. Savransky, PhD (Hospital de Pediatría J. P. Garrahan, L. Schwindling, M. J. Sedano Tous, MD (Hospital Universitario Marques de Valdecilla, Santander Cantabria, Y. Sekiguchi, PhD (Chiba University, Chiba Japan), N. Shahrizaila, MD (Neurology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Malaya), N. J. Silvestri, MD (Buffalo Jacobs School of Medicine S. Sindrup, C. L. Sommer, MD (Universitätsklinikum Würzburg, Würzburg Germany), A. Spyropoulos (Royal Victoria Infirmary, B. Stein, MD (St. Joseph’s Regional Medical Center, Paterson USA), C. Y. Tan, MRCP (Neurology Unit, H. Tankisi, F. Vermeij, M. V. Vytopil, PhD (Tufts University School of Medicine Lahey Hospital P. W. Wirtz, PhD (HagaZiekenhuis, The Hague, W. Waheed, MD (University of Vermont Medical Center, Burlington, USA). Other collaborators were:J. M. Addington, MD (University of Virginia, Charlottesville USA), S. Ajroud-Driss, MD (Northwestern University Feinberg, Chicago USA), G. Antonini, MD (Mental Health and Sensory Organs (NESMOS), Sapienza University, Sant’Andrea Hospital, I. R. Bella, MD (University of Mass Medical School, Worcester USA), T. H. Brannagan, MD (Columbia University, New York City, C. Bunschoten, PhD candidate (Erasmus University Medical Centre, M. Busby, Bradford UK), S. Butterworth, MD (Pinderfields Hospital, Wakefield UK), M. E. Conti, MD (University Hospital Clinicas, S. Chen, PhD (Rutgers, Robert Wood Johnson University Hospital, New Brunswick, A. Doets, the Netherlands), T. E. Feasby, MD (University of Calgary, Calgary Canada), C. Fokke, MD (Gelre Hospital, Zutphen and Apeldoorn, T. Fujioka, MD (Toho University Medical Center, Tokyo Japan), M. P. J. Garssen, PhD (Jeroen Bosch Hospital, ’s Hertogenbosch, J. M. Gilchrist, MD (Soulthern Illinois University School of Medicine, Springfield USA), J. Gilhuis, PhD (Reinier de Graaf Gasthuis, Delft, J. M. Goldstein, MD (Yale University School of Medicine, New Haven, N. A. Goyal, MD (University of California, Irvine USA), R. D. M. Hadden, PhD (King’s College Hospital, London UK), S. T. Hsieh, M. Htut, MD (St. George’s Hospital, I. Illa, K. Jellema, PhD (Haaglanden Medisch Centrum, K. Kaida, PhD (National Defense Medical College, Saitama Japan), H. D. Katzberg, MD (University of Toronto, Toronto Canada), L. Kiers, MD (University of Melbourne, Royal Melbourne Hospital, Parkville Australia), N. Kokubun, MD (Dokkyo Medical University, Tochigi Japan), R. van Koningsveld, PhD (Elkerliek Hospital, Helmond and Deurne, A. J. van der Kooi, J. Y. Kwan, MD (University of Maryland School of Medicine, Baltimore USA), L. Landschoff Lassen, MD (Glostrup Hospital, Glostrup Denmark), V. Lawson, MD (Wexner Medical Center at The Ohio State University, Columbus USA), S. E. Leonhard, M. Mandarakas, PhD (Erasmus University Medical Centre, H. Manji, FRCP (Ipswich Hospital, Ipswich UK), M. G. Mattiazzi, MD (Hospital Militar Central, C. J. McDermott, MD (Royal Hallamshire Hospital, NIHR Clinical, Sheffield UK), Q. D. Mohammad, PhD (National Institute of Neurosciences and Hospital, Dhaka Bangladesh), G. Morís de la Tassa, MD (Hospital UniversitarioCentral de Asturias, Asturias Spain), C. Nascimbene, PhD (Luigi Sacco Hospital, E. H. Niks, R. J. Nowak, M. Osei-Bonsu, PhD (James Cook University Hospital, Middlesbrough UK), R. M. Pascuzzi, MD (University of Indiana School of Medicine, Indianapolis USA), R. C. Roberts, MD (Addenbrooke’s Hospital Cambridge, Cambridge UK), I. Rojas-Marcos, MD (Hospital Univesitario Reina Sofia, Cordoba Spain), J. Roodbol, S. A. Rudnicki, MD (University of Arkansas, Fayetteville USA), G. M. Sachs, MD (University of Rhode Island, Providence USA), A. Schenone, PhD (1. Department of Neurosciences, Rehabilitation Ophthalmology, Genetics and Maternal and Infantile Sciences (DINOGMI), University of Genova, Genova, Italy 2. IRCCS Policlinico San Martino, Genova Italy), K. Sheikh, PhD (The University of Texas Health Science Center at Houston, Houston USA), P. Twydell, DO (Spectrum Health System, Grand Rapids, P. Van Damme, PhD (University Hospital Leuven, J. D. Varrato, DO (Lehigh Valley Health Network, Allentown USA), L. H. Visser, PhD (Elisabeth-TweeSteden Hospital, Tilburg and Waalwijk, H. J. Willison, PhD (University of Glasgow, M. van Woerkom (Erasmus MC, L. Zhou, PhD (Icahn School
المساهمون: C., Verboon, T., Harbo, D. R., Cornblath, R. A. C., Hughe, P. A., Van Doorn, M. P., Lunn, K. C., Gorson, F., Barroso, S., Kuwabara, G., Galassi, H. C., Lehmann, S., Kusunoki, R. C., Reisin, D., Binda, G., Cavaletti, Andersen, Jacobs B. C. H., Md, (Aarhus University Hospital, Phd, Denmark), Aarhu, Attarian, S., (CHU Timone, Phd, France), Marseille, Badrising, U. A., (Leiden University Medical Centre, Phd, Leiden, Netherlands), The, Bateman, K., (Groote Schuur Hospital, Phd, Town, Cape, South-Africa), Benedetti, L., (Ospedale Sant’ Andrea La Spezia, Phd, Spezia, La, Italy), van den Berg, B., (Franciscus Gasthuis, Md, Rotterdam, Van den Bergh, P., Luc, PhD (University Clinic St., Belgium), Leuven, Bertorini, T. E., (The University of Tennessee Health Science Center (UTHSC), Md, USA), Memphi, Bhavaraju-Sanka, R., (University Hospital/ University of Texas Health Science Center, Md, Antonio Texas, San, USA), Bianco (Milan University, M., Clinicala and Research Institute Milan, Humanita, Briani, C., (University of Padova, Md, Italy), Padova, Bürmann, J., (Universitätsklinikum des Saarlandes, Md, Germany), Homburg, Casasnovas, C., Ciberer, PhD (Bellvitge University Hospital - IDIBELL Neurometabolic Diseases Group., Spain), Barcelona, Chao, C. C., (National Taiwan University Hospital, Phd, Taiwan), Taipei, Chavada, G., (Glasgow University, Phd, UK), Glasgow, Claeys, K. G., University Hospitals Leuven, PhD (1., Belgium, Leuven, KU Leuven, 2., Cosgrove, J. S., (Leeds General Infirmary, Md, UK), Leed, Dalakas, M. C., Thomas Jefferson University, MD (1., Usa, Philadelphia, National and Kapodistrian University of Athens, 2., Greece), Athen, Davidson, A., (University of Glasgow, Md, van Dijk, G. W., (Canisius Wilhelmina Hospital, Md, Nijmegen, Dardiotis, E., (University of Thessaly, Md, of Larissa, Hospital, Greece), Larissa, Derejko, M.
بيانات النشر: BMJ Publishing Group
سنة النشر: 2021
المجموعة: Sapienza Università di Roma: CINECA IRIS
مصطلحات موضوعية: guillain-barré syndrome, intravenous immunoglobulins
الوصف: Objective: To compare the disease course in patients with mild Guillain-Barré syndrome (GBS) who were treated with intravenous immunoglobulin (IVIg) or supportive care only. Methods: We selected patients from the prospective observational International GBS Outcome Study (IGOS) who were able to walk independently at study entry (mild GBS), treated with one IVIg course or supportive care. The primary endpoint was the GBS disability score four weeks after study entry, assessed by multivariable ordinal regression analysis. Results: Of 188 eligible patients, 148 (79%) were treated with IVIg and 40 (21%) with supportive care. The IVIg group was more disabled at baseline. IVIg treatment was not associated with lower GBS disability scores at 4 weeks (adjusted OR (aOR) 1.62, 95% CI 0.63 to 4.13). Nearly all secondary endpoints showed no benefit from IVIg, although the time to regain full muscle strength was shorter (28 vs 56 days, p=0.03) and reported pain at 26 weeks was lower (n=26/121, 22% vs n=12/30, 40%, p=0.04) in the IVIg treated patients. In the subanalysis with persistent mild GBS in the first 2 weeks, the aOR for a lower GBS disability score at 4 weeks was 2.32 (95% CI 0.76 to 7.13). At 1 year, 40% of all patients had residual symptoms. Conclusion: In patients with mild GBS, one course of IVIg did not improve the overall disease course. The certainty of this conclusion is limited by confounding factors, selection bias and wide confidence limits. Residual symptoms were often present after one year, indicating the need for better treatments in mild GBS.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34103340; info:eu-repo/semantics/altIdentifier/wos/WOS:000698436500013; firstpage:1080; lastpage:1088; numberofpages:9; journal:JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY; http://hdl.handle.net/11573/1565123Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85107797764
DOI: 10.1136/jnnp-2020-325815
الإتاحة: https://doi.org/10.1136/jnnp-2020-325815Test
http://hdl.handle.net/11573/1565123Test
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.80220E0E
قاعدة البيانات: BASE